Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

20151,207 citationsJournal Articlehybrid Open Access

Authors

The British Heart Foundation and National Institute for Health Research.

Good health and well-being

Published in: The Lancet

Volume 386, Issue 10008, pp. 2059-2068

Field-Weighted Citation Impact: 78.27